12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-13), Seagen's 12-1 Month Momentum % is 63.45%.
The industry rank for Seagen's 12-1 Month Momentum % or its related term are showing as below:
SGEN's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -22.325
vs SGEN: 63.45
Competitive Comparison of Seagen's 12-1 Month Momentum %
For the Biotechnology subindustry, Seagen's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seagen's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seagen's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Seagen's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Seagen 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Seagen's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your